March 2024
1. KANKASA C, Mennecier A, Sakana BLD, Moles JP, et al
   Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial.
   Lancet. 2024 Mar 11:S0140-6736(23)02464-9. doi: 10.1016/S0140-6736(23)02464.
   

   >> Share

   
   December 2023
2. PAPINENI P
   Directly observed therapy.
   Lancet. 2023;400:2265-2266.
   

   >> Share

   
   June 2023
3. HUANG C, Huang L, Wang Y, Li X, et al
   6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
   Lancet. 2023 Jun 12:S0140-6736(23)00810-3. doi: 10.1016/S0140-6736(23)00810.
   

   >> Share

   
   October 2022
4. WONG CKH, Au ICH, Lau KTK, Lau EHY, et al
   Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kon
   Lancet. 2022;400:1213-1222.
   

   >> Share

   
   May 2022
5. 
   Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
   Lancet. 2022 May 2. pii: S0140-6736(22)00519.
   

   >> Share

   
   April 2022
6. DELANY-MORETLWE S, Hughes JP, Bock P, Ouma SG, et al
   Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
   Lancet. 2022 Apr 1. pii: S0140-6736(22)00538.
   

   >> Share

   
   March 2022
7. WATERS L, Marra F, Pozniak A, Cockburn J, et al
   Ritonavir and COVID-19: pragmatic guidance is important.
   Lancet. 2022 Mar 22. pii: S0140-6736(22)00280.
   

   >> Share

   
   February 2022
8. USHER AD
   The global COVID-19 treatment divide.
   Lancet. 2022;399:779-782.
   

   >> Share

   
   
9. SIVA N
   Gilead and ViiV Healthcare reach settlement over HIV drug.
   Lancet. 2022;399:618.
   

   >> Share

   
   January 2022
10. HESKIN J, Pallett SJC, Mughal N, Davies GW, et al
    Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.
    Lancet. 2022;399:21-22.
    

    >> Share

    
    June 2021
11. CORNELL M, Majola M, Johnson LF, Dubula-Majola V, et al
    HIV services in sub-Saharan Africa: the greatest gap is men.
    Lancet. 2021;397:2130-2132.
    

    >> Share

    
    April 2021
12. LOCKMAN S, Brummel SS, Ziemba L, Stranix-Chibanda L, et al
    Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAA
    Lancet. 2021;397:1276-1292.
    

    >> Share

    
    March 2021
13. 
    Human rights and fair access to COVID-19 vaccines: the International AIDS Society-Lancet Commission on Health and Human Rights.
    Lancet. 2021 Mar 24. pii: S0140-6736(21)00708.
    

    >> Share

    
    January 2021
14. HUANG C, Huang L, Wang Y, Li X, et al
    6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
    Lancet. 2021 Jan 8. pii: S0140-6736(20)32656.
    

    >> Share

    
    November 2020
15. HUNG IF, Yuen KY
    Early triple antiviral therapy for COVID-19 - Authors' reply.
    Lancet. 2020;396:1488.
    

    >> Share

    
    
16. LEE N, Ison M, Dunning J
    Early triple antiviral therapy for COVID-19.
    Lancet. 2020;396:1487-1488.
    

    >> Share

    
    October 2020
17. 
    Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    Lancet. 2020 Oct 5. pii: S0140-6736(20)32013.
    

    >> Share

    
    July 2020
18. MAYER KH, Molina JM, Thompson MA, Anderson PL, et al
    Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Lancet. 2020;396:239-254.
    

    >> Share

    
    
19. SPIEGEL HML
    DISCOVER: much accomplished, but not yet for all.
    Lancet. 2020;396:214-215.
    

    >> Share

    
    May 2020
20. WANG Y, Zhang D, Du G, Du R, et al
    Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet. 2020;395:1569-1578.
    

    >> Share

    
    
21. HUNG IF, Lung KC, Tso EY, Liu R, et al
    Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
    Lancet. 2020 May 8. pii: S0140-6736(20)31042.
    

    >> Share

    
    
22. SHALHOUB S
    Interferon beta-1b for COVID-19.
    Lancet. 2020 May 8. pii: S0140-6736(20)31101.
    

    >> Share

    
    April 2020
23. MULLARD A
    Flooded by the torrent: the COVID-19 drug pipeline.
    Lancet. 2020;395:1245-1246.
    

    >> Share

    
    March 2020
24. KROWN SE, Moser CB, MacPhail P, Matining RM, et al
    Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.
    Lancet. 2020 Mar 5. pii: S0140-6736(19)33222.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share